Cargando…
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (Cli...
Autores principales: | Sander, Frida Ewald, Rydström, Anna, Bernson, Elin, Kiffin, Roberta, Riise, Rebecca, Aurelius, Johan, Anderson, Harald, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B., Martner, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884940/ https://www.ncbi.nlm.nih.gov/pubmed/26863635 http://dx.doi.org/10.18632/oncotarget.7210 |
Ejemplares similares
-
Role of natural killer cell subsets and natural cytotoxicity receptors for
the outcome of immunotherapy in acute myeloid leukemia
por: Martner, Anna, et al.
Publicado: (2015) -
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
por: Sander, Frida Ewald, et al.
Publicado: (2017) -
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
por: Martner, Anna, et al.
Publicado: (2015) -
Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
por: Bernson, E, et al.
Publicado: (2017) -
Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2021)